Insulin degludec and liraglutide - Biologic Drug Details

Summary for insulin degludec and liraglutide

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for insulin degludec and liraglutide

Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists
Established Pharmacologic Class	GLP-1 Receptor Agonist Insulin Analog
Chemical Structure	Glucagon-Like Peptide 1 Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin degludec and liraglutide Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin degludec and liraglutide Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	XULTOPHY 100/3.6	insulin degludec and liraglutide	Injection	208583		2036-02-19	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	XULTOPHY 100/3.6	insulin degludec and liraglutide	Injection	208583		2026-07-25	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	XULTOPHY 100/3.6	insulin degludec and liraglutide	Injection	208583		2038-11-15	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	XULTOPHY 100/3.6	insulin degludec and liraglutide	Injection	208583		2036-03-14	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	XULTOPHY 100/3.6	insulin degludec and liraglutide	Injection	208583		2038-07-06	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	XULTOPHY 100/3.6	insulin degludec and liraglutide	Injection	208583		2039-06-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin degludec and liraglutide Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	XULTOPHY 100/3.6	insulin degludec and liraglutide	Injection	208583		2032-10-25	Patent claims search

International Patents for insulin degludec and liraglutide

Country	Patent Number	Estimated Expiration
China	107847520
European Patent Office	4582436
Chile	2013002692
Canada	2877539
Australia	2006272555
Brazil	112013023816

Market Dynamics and Financial Trajectory for Insulin Degludec and Liraglutide

Last updated: February 23, 2026

What is the current market size for insulin degludec and liraglutide?

The global market for diabetes biologics, including insulin degludec and liraglutide, is expanding rapidly. The combined market size was valued at approximately USD 18 billion in 2022 with a compound annual growth rate (CAGR) of 8-10%. Insulin degludec contributes an estimated USD 3.5 billion, while liraglutide’s segment accounts for around USD 4.5 billion of that figure (Grand View Research, 2022). The total market forecast projects a valuation reaching USD 35–40 billion by 2030.

How does market adoption influence volume and revenue projections?

Adoption rates are driven by clinical advantages, such as reduced hypoglycemia risk, longer duration of action, and convenience. Insulin degludec’s once-daily dosing appeals to patients and providers, supporting a higher uptake rate. Liraglutide's efficacy in weight reduction and cardiovascular outcomes promotes its adoption for both type 2 diabetes and obesity indications.

The volume of prescriptions for insulin degludec increased at a CAGR of 12% between 2018 and 2022, while liraglutide prescriptions grew at 15% during the same period (IQVIA, 2022). This growth correlates with expanding approval in emerging markets and increased formulary inclusion.

What are the key drivers influencing revenue growth?

• Patent and exclusivity period: Liraglutide's patent expiry is expected in 2028, leading to potential biosimilar competition. Insulin degludec's patent protection extends until 2030, supporting revenue retention.
• Pricing strategies: Premium pricing continues, justified by clinical benefits, but pricing pressures from biosimilars could impact margins post-patent expiry.
• Regulatory approvals and expanded indications: The FDA approved liraglutide for obesity and cardiovascular risk reduction. Novo Nordisk and Sanofi are pursuing expanded indications for insulin degludec.
• Market penetration in emerging markets: Increasing access and manufacturing capabilities in Asia and Latin America are expanding customer bases.

How do competitive pressures and biosimilar entries shape the financial outlook?

Biosimilar development for liraglutide is underway in China and Europe, with potential market entry by 2028-2030. This could reduce prices and margins, especially in cost-sensitive markets. Insulin degludec faces similar biosimilar competition from biospecifics seeking approval in the U.S. and Europe.

The threat of biosimilars remains credible, but brand loyalty, clinical differentiation, and expanded indications serve to delay erosion. Companies investing in lifecycle management—such as fixed-dose combinations or novel delivery systems—can sustain revenue streams.

What are growth forecasts and investment trends?

Projections estimate annual revenues for insulin degludec and liraglutide will reach USD 10–12 billion combined by 2030. Investment in research and development (R&D), particularly in biosimilar development and novel delivery devices, exceeds USD 2 billion annually.

Major participants—Novo Nordisk, Sanofi, Eli Lilly—continue to prioritize these products, increasing R&D budgets to maintain competitive advantage. Novo Nordisk’s recent approval of the once-weekly insulin degludec variant and Eli Lilly’s new GLP-1 formulations indicate ongoing innovation fueling future revenue growth.

What potential regulatory and policy changes could impact future growth?

Pricing adjustments, reimbursement reforms, and tighter regulation of biosimilar markets could influence market dynamics. Countries adopting value-based pricing models may limit initial pricing premiums, pressuring margins. However, increased global burden of diabetes, especially type 2, sustains demand.

Summary table: Market and financial metrics (2022–2030)

Metric	2022 (Actual)	2030 (Forecast)
Total market size	USD 18 billion	USD 35–40 billion
Insulin degludec revenue	USD 3.5 billion	USD 6–8 billion
Liraglutide revenue	USD 4.5 billion	USD 8–10 billion
CAGR (2022–2030)	8–10%	8–10%
Biosimilar entry date	2028–2030	Market share reduction possible

Key Takeaways

• The biologics market for insulin degludec and liraglutide is expanding, driven by increased adoption, expanded indications, and market penetration in emerging economies.
• Patent protections and clinical differentiation support revenue persistence, but biosimilar competition remains a significant risk post-2028.
• Continued innovation, lifecycle management, and regional expansion are critical to sustaining revenue growth.
• Pricing pressures, reform policies, and biosimilar entries are key uncertainties affecting future financial trajectory.
• Investment in R&D for new formulations, delivery methods, and indications will be essential to maintain market share.

FAQs

Q1: When are biosimilars for liraglutide expected to enter the market?
A1: Biosimilar development is underway in China and Europe, with approvals potentially between 2028 and 2030.

Q2: How will regulatory changes influence pricing and reimbursement?
A2: Policies favoring value-based pricing and cost containment could reduce profitability and slow revenue growth.

Q3: What is the impact of expanded indications on revenue projections?
A3: Approval for obesity and cardiovascular prevention broadens patient bases and increases sales volume.

Q4: Which companies are leading in insulin degludec and liraglutide development?
A4: Novo Nordisk, Sanofi, and Eli Lilly are primary competitors investing heavily in R&D and new formulations.

Q5: How does emerging market growth affect the overall market?
A5: Rapid market entry and increasing healthcare spending in Asia and Latin America contribute positively to global revenues.

---

References

1. Grand View Research. (2022). Market size & growth forecast for diabetes biologics.
2. IQVIA. (2022). Prescription volume and growth metrics for diabetes biologics.